A population-based cohort study showed that cardio-renal-metabolic conditions (CVD, CKD, and T2D) and their overlap were increasingly common among US adults over the last 2 decades.

EASD 2023 A small randomized study showed that treatment with GLP-1RA semaglutide on top of empagliflozin did not have an additional beneficial effect on albuminuria in patients with T2D and albuminuria compared with placebo.

ESC Congress 2023 In the RED-CVD study, it was investigated whether a new diagnostic strategy could increase the number of new CVD diagnoses in primary care patients with COPD or T2D compared with usual care. Amy Groenewegen shares the results.

EASD 2023 A real-life study investigated the prescription on glucose lowering agents in Swedish patients with T2D and CAD from 2010 to 2021.

What are the effects of SGLT2 inhibitors on CV outcomes across different subgroups of patients? This was investigated in a meta-analysis of 13 RCTs in patients with HF, T2D or CKD, and in patients with varying combinations of these diseases.

ESC Congress 2023 New recommendations in the 2023 ESC guidelines for the management of CVD in patient with diabetes include focus on glucose-lowering medication with proven CV benefit and/or safety and the new SCORE2-Diabetes risk score.

ESC Congress 2023 In the RED-CVD trial, it was shown that a proactive diagnostic intervention strategy improves early diagnosis of CVD in primary care patients with COPD and/or T2D.

A population-based cohort study showed that loneliness, but not social isolation, was associated with a higher CVD risk in patients with DM. Loneliness also ranked higher in relative strength for predicting CVD risk than lifestyle risk factors such as smoking and diet.

EAS Congress 2023 Some studies have demonstrated directionality from inflammation to diabetes. The next question is: can anti-inflammatory therapies halt the progression to diabetes?

A serial cross-sectional analysis using data of the NHANES database investigated whether the prevalence of CV risk factors among young US adults changed from 2009 to March 2020.

Does intermittent fasting plus early time-restricted eating provide greater improvements in glycemic control, weight management or CV markers compared to calorie restriction or standard care in adults at risk of T2DM? The authors investigated this in a three-arm parallel group sequential RCT.

A pooled analysis of patients with established ASCVD showed a 10-year risk of recurrent ASCVD events of 20% and a lifetime risk of 54%. Theoretically, optimization of both lifestyle and medications could reduce both risks and add 7.3 event-free years.